Successful Use of Upadacitinib in Treating a Child With Epidermolysis Bullosa Pruriginosa: A Case Report and Literature Review

Epidermolysis bullosa pruriginosa (EBP) is a rare subtype of dystrophic epidermolysis bullosa (DEB) that poses significant management challenges. In this case report, a 12-year-old female with EBP was successfully treated with upadacitinib at a dosage of 15 mg once daily for a period of 12 weeks, after which the frequency was changed to every other day. A review of the literature identified 19 cases successfully treated with a Janus kinase inhibitor (JAKi) suggesting that JAKis are a promising option for EBP patients.